ProSensa B.V. to Present at J.P. Morgan Healthcare Conference
1/3/2013 6:30:47 AM
More...
|
ProSensa B.V. Raises Around $30 Million to Progress Exon-Skipping Antisense Oligonucleotides
1/25/2012 7:13:48 AM
More...
|
ProSensa B.V. Named Most Innovative European Biotech SME
11/8/2011 10:34:14 AM
More...
|
GlaxoSmithKline (GSK) and ProSensa B.V. Announce Start of Phase III Study of Investigational Duchenne Muscular Dystrophy Medication
1/19/2011 8:08:56 AM
More...
|
ProSensa B.V. Receives £7.5 Million ($11.9 Million) Milestone Payment as Part of Its Program with GlaxoSmithKline (GSK) in Duchenne Muscular Dystrophy
10/13/2010 6:17:08 AM
More...
|
ProSensa B.V. and GlaxoSmithKline (GSK) Initiate Development of Four Additional Products Under Existing Alliance in Duchenne Muscular Dystrophy
6/23/2010 6:48:51 AM
More...
|
ProSensa B.V. Initiates Clinical Development of PRO044 in an Open Label Phase I/II Study
3/30/2010 4:13:38 PM
More...
|
GlaxoSmithKline (GSK) in $680 Million RNA Deal with ProSensa B.V.
10/13/2009 7:48:17 AM
More...
|
ProSensa B.V. Raises E18 Million
12/18/2008 7:50:31 AM
More...
|
CureDuchenne, AVI BioPharma, Inc. (AVII), And ProSensa B.V. Exon Skipping Hosting Conference for Duchenne Muscular Dystrophy
10/14/2008 10:19:01 AM
More...
|
|